In line with PI3K/mTOR inhibitors, various kinase inhibitors have entered into clinical trials for gastrointestinal cancers [194], thyroid carcinoma [195], breast cancer [196], and endocrine tumors [197]. The gene discussed is MTOR; the disease is breast carcinoma.